Penumbra (PEN) Cash & Equivalents Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -22.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 23.57% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -7.71% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 156.03% |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | -35.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.84% |
| Dec 31, 2025 | -42.39% |
| Sep 30, 2025 | 14.46% |
| Jun 30, 2025 | 46.28% |
| Mar 31, 2025 | 68.55% |
| Dec 31, 2024 | 93.69% |
| Sep 30, 2024 | 178.37% |
| Jun 30, 2024 | 152.55% |
| Mar 31, 2024 | 135.63% |
| Dec 31, 2023 | 139.75% |
| Sep 30, 2023 | 83.72% |
| Jun 30, 2023 | 96.05% |
| Mar 31, 2023 | 38.91% |
| Dec 31, 2022 | 17.65% |
| Sep 30, 2022 | -17.27% |
| Mar 31, 2022 | 22.52% |
| Dec 31, 2021 | -14.77% |
| Sep 30, 2021 | -17.26% |
| Mar 31, 2021 | -23.22% |
| Dec 31, 2020 | -4.27% |
| Sep 30, 2020 | -28.20% |
| Jun 30, 2020 | 73.93% |
| Mar 31, 2020 | 6.79% |
| Dec 31, 2019 | 7.26% |
| Sep 30, 2019 | 133.72% |
| Jun 30, 2019 | 29.40% |
| Mar 31, 2019 | 33.99% |
| Dec 31, 2018 | 33.99% |
| Sep 30, 2018 | -27.25% |
| Jun 30, 2018 | -22.03% |
| Mar 31, 2018 | -53.71% |
| Dec 31, 2017 | 282.57% |
| Sep 30, 2017 | 313.86% |
| Jun 30, 2017 | 450.35% |
| Mar 31, 2017 | 521.28% |
| Dec 31, 2016 | -32.29% |
| Sep 30, 2016 | -90.03% |
| Jun 30, 2016 | -62.15% |
| Mar 31, 2016 | 116.50% |
| Dec 31, 2015 | 494.13% |
| Sep 30, 2015 | 1,843.06% |